Assembly Biosciences (NASDAQ:ASMB) Stock Price Crosses Below 50 Day Moving Average - Here's Why

Assembly Biosciences logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Assembly Biosciences shares fell below their 50-day moving average, trading as low as $22.07 versus the average of $22.48; the stock last traded at $22.39.
  • The company reported a quarterly loss of $0.93 per share, wider than analysts’ $0.66 estimate, while revenue of $2.96 million also missed expectations of $9.07 million.
  • Analyst views are mixed, but the consensus rating is Moderate Buy, with a $46.50 average price target; ratings include four Buys, one Hold and one Sell.
  • Five stocks to consider instead of Assembly Biosciences.

Shares of Assembly Biosciences, Inc. (NASDAQ:ASMB - Get Free Report) passed below its 50-day moving average during trading on Wednesday. The stock has a 50-day moving average of $22.48 and traded as low as $22.07. Assembly Biosciences shares last traded at $22.39, with a volume of 486,995 shares trading hands.

Analyst Upgrades and Downgrades

ASMB has been the subject of a number of recent research reports. Weiss Ratings reiterated a "sell (d-)" rating on shares of Assembly Biosciences in a research note on Thursday, October 15th. HC Wainwright reaffirmed a "buy" rating and issued a $50.00 price target on shares of Assembly Biosciences in a report on Tuesday, August 18th. Zacks Research cut Assembly Biosciences from a "strong-buy" rating to a "hold" rating in a research report on Monday, November 9th. UBS Group lowered their price target on shares of Assembly Biosciences from $52.00 to $48.00 and set a "buy" rating on the stock in a report on Tuesday, November 3rd. Finally, Mizuho set a $53.00 target price on Assembly Biosciences in a research note on Tuesday, September 1st. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $46.50.

Check Out Our Latest Research Report on ASMB

Assembly Biosciences Trading Down 0.5%

The business has a fifty day moving average price of $22.48 and a 200-day moving average price of $26.78. The stock has a market capitalization of $458.55 million, a PE ratio of 27.64 and a beta of 1.26.

Assembly Biosciences (NASDAQ:ASMB - Get Free Report) last issued its earnings results on Thursday, November 12th. The biopharmaceutical company reported ($0.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by ($0.27). Assembly Biosciences had a negative return on equity of 4.40% and a negative net margin of 16.57%. The firm had revenue of $2.96 million during the quarter, compared to analysts' expectations of $9.07 million. On average, equities analysts anticipate that Assembly Biosciences, Inc. will post 2.28 earnings per share for the current fiscal year.

Insider Activity at Assembly Biosciences

In related news, insider Anuj Gaggar sold 2,593 shares of Assembly Biosciences stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $19.62, for a total value of $50,874.66. Following the transaction, the insider owned 53,800 shares in the company, valued at $1,055,556. This trade represents a 4.60% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Jason Okazaki sold 6,202 shares of the business's stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $19.62, for a total transaction of $121,683.24. Following the completion of the sale, the chief executive officer directly owned 195,532 shares of the company's stock, valued at $3,836,337.84. This represents a 3.07% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders have sold 12,115 shares of company stock valued at $237,696. Insiders own 3.50% of the company's stock.

Institutional Investors Weigh In On Assembly Biosciences

Hedge funds and other institutional investors have recently modified their holdings of the stock. Seven Fleet Capital Management LP grew its position in Assembly Biosciences by 671.5% during the 2nd quarter. Seven Fleet Capital Management LP now owns 433,147 shares of the biopharmaceutical company's stock worth $11,903,000 after acquiring an additional 377,000 shares during the last quarter. Bank of New York Mellon Corp bought a new stake in Assembly Biosciences during the 2nd quarter valued at $660,000. Stempoint Capital LP increased its position in shares of Assembly Biosciences by 18.3% in the first quarter. Stempoint Capital LP now owns 185,435 shares of the biopharmaceutical company's stock valued at $5,146,000 after acquiring an additional 28,707 shares during the period. Goldman Sachs Group Inc. increased its position in shares of Assembly Biosciences by 39.1% in the third quarter. Goldman Sachs Group Inc. now owns 191,747 shares of the biopharmaceutical company's stock valued at $4,504,000 after acquiring an additional 53,914 shares during the period. Finally, Jump Financial LLC bought a new position in shares of Assembly Biosciences during the third quarter valued at about $1,078,000. Institutional investors own 19.92% of the company's stock.

Assembly Biosciences Company Profile

(Get Free Report)

Assembly Biosciences is a clinical-stage biotechnology company focused on developing oral antiviral therapies for viral infections. Its research programs target hepatitis B virus (HBV) and herpesviruses, including herpes simplex virus. The company's pipeline includes investigational antiviral candidates designed to interfere with key steps in viral replication. Assembly has also worked with Gilead Sciences on antiviral development, including programs targeting herpesviruses. Its therapies remain under investigation and are not approved medicines.

Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Assembly Biosciences Right Now?

Before you consider Assembly Biosciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Assembly Biosciences wasn't on the list.

While Assembly Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines